Risk Factors for Pulmonary Hypertension in Sickle Cell Patients
Summary and Comment Subscription required
Genetic variants in SCD patients were associated with PH.
Lenalidomide for Relapsed Chronic Lymphocytic Leukemia Patients
Lenalidomide, given as a continuous daily oral dose, showed antitumor activity in one third of heavily pretreated CLL patients.
Perioperative Thrombosis Prevention in Cancer Patients
Summary and Comment Subscription required
Venous thromboembolism was less common with low-molecular-weight heparins versus unfractionated heparin, but survival was unaffected.
Thromboses, Microparticles, and Thrombin Generation: How Are They Linked?
Summary and Comment Subscription required
Patients with thrombosis had more microparticle-mediated thrombin generation than did normal controls.
Rivaroxaban for Thromboprophylaxis After Joint Replacement
In two large, randomized studies, rivaroxaban was superior to enoxaparin in preventing venous thrombosis.
By David Green, MD, PhD
June 25, 2008
Covering:
Eriksson BI et al., N Engl J Med 2008 Jun 26; 358:2765
Lassen MR et al., N Engl J Med 2008 Jun 26; 358:2776
Sleep Disturbance and Cancer
Summary and Comment Subscription required
Patients with advanced cancer had difficulty maintaining both sleep and waking states.
Reversing Immunopathology with Rituximab in Cryoglobulinemia Patients
Summary and Comment Subscription required
B-cell depletion therapy with rituximab could be effective for patients with HCV-related mixed cryoglobulinemia.
Extended Androgen-Deprivation Therapy for Prostate Cancer
Summary and Comment Subscription required
Disease-free survival at 10 years was better for patients who received post-radiation ADT than for those who did not.
Salvage Radiotherapy in Radical Prostatectomy Patients with PSA-Only Relapses
Summary and Comment Subscription required
Salvage therapy was most beneficial for men who received therapy within 2 years of biochemical failure.
Why Is Warfarin Such a Dangerous Drug?
Many patients who receive warfarin would have been excluded from the trials in which the drug’s efficacy versus safety was assessed.
